Roche's personalized cancer treatment wins FDA approval

Credit: REUTERS/Arnd Wiegmann

The U.S. Food and Drug Administration approved Roche Holding AG's personalized cancer treatment, the agency said on Thursday.

Aug 15 (Reuters) - The U.S. Food and Drug Administration approved Roche Holding AG's ROG.S personalized cancer treatment, the agency said on Thursday.

The treatment, Rozlytrek, is a tyrosine kinase inhibitor that targets patients who must be identified via genetic profiling. The treatment is used to treat certain types of solid tumors and a type of lung cancer.

(Reporting by Aakash Jagadeesh Babu and Manojna Maddipatla in Bengaluru; Editing by Arun Koyyur)

((Aakash.B@thomsonreuters.com; within the U.S. +16462238780, outside the U.S. +91 80 67491576; Reuters Messaging: Twitter: @JagadeeshAakash))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More